Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Sheridan M. Hoy
American Journal of Clinical Dermatology (2022) Vol. 24, Iss. 1, pp. 143-151
Open Access | Times Cited: 17

Showing 17 citing articles:

The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies
George Mihai Nițulescu, Gheorghe Stancov, Oana Cristina Șeremet, et al.
Molecules (2023) Vol. 28, Iss. 14, pp. 5359-5359
Open Access | Times Cited: 35
Impact of Crisaborole in Treatment-Experienced Patients With Mild-to-Moderate Atopic Dermatitis
Linda Stein Gold, Wynnis L. Tom, Vivian Y. Shi, et al.
Dermatitis (2024) Vol. 35, Iss. 1, pp. 84-91
Open Access | Times Cited: 5
Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents
Carlo Caffarelli, Arianna Giannetti, Giuliana Giannì, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 13
Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives
Lawrence F. Eichenfield, J. Z. Liu, Simran Marwaha, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 3, pp. 685-696
Open Access | Times Cited: 4
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Connie Kang
Drugs (2024) Vol. 84, Iss. 5, pp. 579-586
Open Access | Times Cited: 4
Janus kinase inhibitors for the treatment of lichen Sclerosus: A systematic review
Chin‐Hsuan Shen, Shu-Hui Wang, Ching‐Chi Chi
British Journal of Clinical Pharmacology (2025)
Closed Access
Efficacy and safety of BSZY cream for mild-to-moderate atopic facial dermatitis: protocol of a randomised, double-blind, controlled trial
P.N. Wang, Xuqiang Wei, Linyan Cheng, et al.
BMJ Open (2025) Vol. 15, Iss. 3, pp. e087149-e087149
Open Access
American Academy of Dermatology Annual Meeting: Orlando, FL, USA, 7-11 March 2025
Kathy A Fraser
American Journal of Clinical Dermatology (2025)
Closed Access
Treatment of granulomatous perioral dermatitis with 1.5% topical ruxolitinib cream
Sophia S. Tran, Benjamin Ungar, Patrick M. Brunner
JAAD Case Reports (2024) Vol. 47, pp. 1-3
Open Access | Times Cited: 2
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Adelaide A. Hebert, Carsten Flohr, Hwanhee Hong, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 2
Pruritogenic Mediators and New Antipruritic Drugs in Atopic Dermatitis
Dimitra Koumaki, Stamatios Gregoriou, George Evangelou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 6, pp. 2091-2091
Open Access | Times Cited: 6
The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
Deesha Desai, Ambika Nohria, Kristen Lo Sicco, et al.
JAAD Case Reports (2024) Vol. 50, pp. 141-143
Open Access | Times Cited: 1
Topical Prescription Management
Katie Lovell, Bradley G. Ackerson, Ryan K. Thorpe, et al.
Advances in experimental medicine and biology (2024), pp. 117-129
Closed Access | Times Cited: 1
Beyond Avoidance: Advanced Therapies for Contact Dermatitis
Lu Yin, Benjamin Ungar, Emma Guttman‐Yassky, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 9, pp. 2260-2267
Closed Access | Times Cited: 1
Emerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials
Ogechi Obed, Albert C. Chong, Malcolm Su, et al.
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 3, pp. 233-249
Closed Access
Addressing Unmet Needs in Atopic Dermatitis: Evaluating Disease-Modifying Capabilities of Current and Emerging Therapies
Sarah G Brooks, Lourdes M Lopez, Kayla D. Mashoudy, et al.
Dermatitis (2024)
Closed Access
Atopic Dermatitis: A Review of Diagnosis and Treatment
Jack Jeskey, Christine Kurien, Henry Blunk, et al.
The Journal of Pediatric Pharmacology and Therapeutics (2024) Vol. 29, Iss. 6, pp. 587-603
Closed Access
Page 1

Scroll to top